NCT01670994View on ClinicalTrials.gov

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

August 14, 2012

Primary Completion Date

September 9, 2015

Study Completion Date

September 9, 2015

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

BIOLOGICAL

ALT-801

Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle

Trial Locations (1)

52242

University of Iowa Hospitals, Iowa City

Sponsors

Lead Sponsor

Altor BioScience

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Altor BioScience

INDUSTRY

NCT01670994 - QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter